200 related articles for article (PubMed ID: 18221038)
1. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
Caraglia M; Marra M; Meo G; Addeo SR; Tagliaferri P; Budillon A
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):209-22. PubMed ID: 18221038
[TBL] [Abstract][Full Text] [Related]
2. Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.
Tagliaferri P; Tassone P; Blotta S; Viscomi C; Grillone F; Budillon A; Caraglia M; Venuta S
Curr Drug Targets; 2005 May; 6(3):289-300. PubMed ID: 15857289
[TBL] [Abstract][Full Text] [Related]
3. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
[TBL] [Abstract][Full Text] [Related]
7. Targeting the EGF/HER Ligand-Receptor System in Cancer.
Esparís-Ogando A; Montero JC; Arribas J; Ocaña A; Pandiella A
Curr Pharm Des; 2016; 22(39):5887-5898. PubMed ID: 27426127
[TBL] [Abstract][Full Text] [Related]
8. Emerging paradigms and recent progress in targeting ErbB in cancers.
Stoup N; Liberelle M; Lebègue N; Van Seuningen I
Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
[TBL] [Abstract][Full Text] [Related]
10. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
11. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
12. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.
Peipp M; Dechant M; Valerius T
MAbs; 2009; 1(6):590-9. PubMed ID: 20068398
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor as a target for anti-cancer agent design.
Cao J; Fang H; Wang B; Ma C; Xu W
Anticancer Agents Med Chem; 2010 Jul; 10(6):491-503. PubMed ID: 20698825
[TBL] [Abstract][Full Text] [Related]
15. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
16. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
Mitchell RA; Luwor RB; Burgess AW
Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
[TBL] [Abstract][Full Text] [Related]
19. ErbB antagonists patenting: "playing chess with cancer".
Aifa S; Rebai A
Recent Pat Biotechnol; 2008; 2(3):181-7. PubMed ID: 19075865
[TBL] [Abstract][Full Text] [Related]
20. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
